Here’s a roundup of the latest dealflow and investment news:
- RainDance Technologies raises $37.5 million in Series D financing
RainDance Technologies Inc., a provider of microdroplet-based solutions for single molecule and single cell analysis, announced that it closed a Series D financing round of $37.5 million. The financing was co-led by new investor Quaker BioVentures and existing investor Mohr Davidow Ventures. Existing investors Alloy Ventures and Acadia Woods LLC also participated in the financing round. Sherrill Neff from Quaker BioVentures and Jeffrey Samberg from Acadia Woods will join the RainDance Board of Directors.
Read more - Fresenius Medical Care offers of $500 million and €300 million senior notes for refinancing and acquisitions
Fresenius Medical Care AG & Co. KGaA, the world’s largest provider of dialysis products and services, announced its intention to sell $500 million of senior unsecured notes due 2021 issued by Fresenius Medical Care US Finance, Inc. and €300 million of senior unsecured notes due 2021 issued by FMC Finance VII S.A. Both issuers are wholly owned subsidiaries of the company.
Read more - SensibleSelf drums up seed funding
Cambridge, Mass.-based SensibleSelf, which manufactures an ultra-thin RFID device for monitoring healthy behavior, landed pre-angel funding from Boston early-stage investor Bill Warner, according to Mass High Tech.
Read more - Diavibe looks to bring in $450,000
R.I.-based Diavibe is working through a $250,000 private funding round in applying for a $200,000 grant from Women and Infants Hospital of Providence to build and test 200 prototypes for reducing the pain of at-home injections, reports Mass High Tech.
Read more - Digital Assent secures $2 Million series A financing to grow PatientPad point-of-care network
Atlanta-based Digital Assent, provider of the PatientPad self-service patient check-in and patient education solution, announces the closing of a $2 million Series A round of equity financing led by Imlay Investments, Fulcrum Equity Partners and BLH Venture Partners.
Read more - BlackBio raises $3 million
Spain-based BlackBio raised $3 million. The funds will be used to continue development of diagnostic tools and international expansion, according to GenomeWeb.
Read more - Fluidigm drums up $5 million
South San Francisco-based Fluidigm Corp. raised $5 million from 49 unnamed investors in an debt and options-based round, according to a Securities & Exchange Commission filing.
Read more - Spherix closes registered direct offering of $2.77 million in common stock and warrants
Spherix Inc. (NSDQ:SPEX), an innovator in biotechnology for therapy in diabetes, metabolic syndrome and atherosclerosis; and providers of technical and regulatory consulting services to food, supplement, biotechnology and pharmaceutical companies, announced the closing of previously reported agreements to sell $2.77 million of shares of its common stock and warrants to purchase shares of its common stock in a registered direct offering to institutional investors. The Company intends to use the net proceeds of approximately $2.6 million from the offering to continue the development of D-tagatose for diabetes and triglycerides, as well as for general corporate purposes.
Read more - Thermo Fisher Scientific notifies holders of 3.25 percent convertible motes of option to require the company to purchase notes
Thermo Fisher Scientific Inc. (NYSE:TMO), a leader in serving science, announced that it has provided notice to holders of its 3.25 percent convertible senior subordinated notes due March 1, 2024, as required by the indenture governing the notes, that the holders have the option to require the company to purchase the notes on March 1, 2011. The purchase of the notes would be at par, together with accrued and unpaid interest from Sept. 1, 2010.
Read more - Generex announces $3 illion investment
Generex Biotechnology Corp. (OTC:GNBT) announced that it entered into a securities purchase agreement with certain institutional investors on Jan. 24, 2011. The investors agreed to purchase up to $6 million of shares of the company’s common stock and warrants to purchase shares of common stock. At the initial closing, the investors will purchase an aggregate of 12,000,000 shares of common stock together with warrants to purchase an aggregate of 12,000,000 shares of common stock for a total purchase price of $3,000,000. The investors will also have the option to purchase up to an additional $3,000,000 of shares of common stock and warrants to purchase shares of common stock during the 60 days following the initial closing. The purchase price of any additional shares purchased by the investors, and the exercise price of any additional warrants issued to them, will be $0.25 per share.
Read more - Computable Genomix announces investment
Memphis-based Computable Genomix today announced that it has secured an investment to pilot a novel process for developing genetic biomarker tests. Biomarkers are used to predict how a person will respond to drug therapy or to determine their risk of contracting a disease. Memphis-based venture capital firm Innova is funding Computable’s effort to stake a claim in the biomarker market.
Read more
